Citations

Clear

499 citation(s) found for "Tracy, PB".

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Valtis, Yannis K. , Lin, Chenyu , Devlin, Sean, Curran, Kevin J., Wang, Xiuyan , Jeyakumar, Nikeshan , Miller, Katharine, Zhang, Amy , Darobi, Ali Al, Sasine, Joshua , Kopmar, Noam E. , Tsai, Stephanie B., Solh, Melhem , Tan, Virginia, Ramakrishnan, Aravind , Shaughnessy, Paul , Mountjoy, Luke , Hoeg, Rasmus T. , Schwartz, Marc S. , Tracy, Sean , Moore, Jozal , Bobillo, María Silvina Odstrcil , Connor, Matthew P. , Ladha, Abdullah , Sutherland, Katherine C. , Muffly, Lori , Park, Jae H. , Shah, Nirali N , Jeyakumar, Nikeshan , Sasine, Joshua , Advani, Anjali S , Chen, Evan , Hilal, Talal , Shah, Bijal , Faramand, Rawan , Bezerra, Evandro D , Dykes, Kaitlyn C , Logan, Aaron C , Moore, Jozal , Odstrcil Bobillo, Silvina , Frey, Noelle V , Connor, Matthew , Ladha, Abdullah , Dholaria, Bhagirathbhai R , Sutherland, Katherine , Roloff, Gregory W , Muffly, Lori , Lin, Chenyu , Nemirovsky, David , Rejeski, Kai , Curran, Kevin Joseph , Kota, Vamsi , Muhsen, Ibrahim N. , Aldoss, Ibrahim , Advani, Anjali S. , Reshef, Ran , Tsai, Stephanie B., Hilal, Talal , Shah, Bijal , Faramand, Rawan , Bezerra, Evandro D. , Battiwalla, Minoo , Mathews, John Abraham , Dykes, Kaitlyn C. , Kumaran, Muthu Sendhil , Schwartz, Marc, Frey, Noelle V. , Dholaria, Bhagirathbhai , Roloff, Gregory W.

Mayo Clinic

Blood Advances | October 6, 2025 | Volume: 10 | Issue: 1 | Pages: 276-288

10.1182/bloodadvances.2025017526 | PMID 41052404 Get It

Abstract Chimeric antigen receptor (CAR) T-cell (CAR-T) treatment for B-cell acute lymphoblastic leukemia (ALL) induces high initial response rates, but most patients relapse. Low disease burden (often defined as <5% blasts in the bone marrow) is associated with better outcomes. CAR HEMATOTOX (HT) is a score using prelymphodepletion hematologic and inflammatory parameters to predict outcomes in lymphoma. Here, we assess its prognostic utility in a large multicenter adult B-cell ALL cohort. Patients who received brexucabtagene autoleucel across 33 centers in North America were included as part of the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) consortium. An independent cohort of 61 patients with ALL treated with an investigational CD19 CAR-T therapy at 1 center was also described. Among 199 ROCCA consortium patients, 43 (22%) patients with HTlow scores had lower rates of delayed neutrophil recovery than those with HThigh scores (26% vs 52%, P = .002) and fewer severe infections (2.5% vs 18.8%, P = .011). They also had higher response rates, overall survival (OS), and event-free survival (EFS), as well as lower nonrelapse mortality and cumulative incidence of relapse. The survival differences remained significant after multivariable adjustment for disease burden and other covariates. In the investigational cohort of 61 patients, patients with HTlow scores had improved OS and EFS, as well as higher peak CAR-T expansion. In summary, CAR HT score is a prognostic factor independent of disease burden in adult ALL. HTlow score is associated with superior outcomes after CD19 CAR-Ts and higher CAR-T expansion in a single-center cohort. These trials were registered at www.clinicaltrials.gov as #NCT01044069 and #NCT01860937.
Current practices and trends in surgical decision‐making for children with Lennox–Gastaut syndrome: A cross‐sectional survey by the Pediatric Epilepsy Research Consortium
Chiu, Michelle , Keator, Cynthia, Warren, Aaron E. L. , Knowles, Juliet K. , Samanta, Debopam , Dixon‐Salazar, Tracy , Seinfeld, Syndi, Paolicchi, Juliann , Vidaurre, Jorge , Shellhaas, Renée A. , Clarke, Dave , Bhalla, Sonam , Depositario‐Cabacar, Dewi, Haridas, Babitha , Stafstrom, Carl E. , Erdemir, Gozde , Karakas, Cemal , Chiu, Michelle Y , Koh, Hyun Yong , Vidaurre, Jorge , Patel, Anup D , Loddenkemper, Tobias , Shellhaas, Renée A , Clarke, Dave F , Fine, Anthony , Bhalla, Sonam , Stafstrom, Carl E , Erdemir, Gozde , Karakas, Cemal , Knowles, Juliet K , Patel, Anup D. , Loddenkemper, Tobias , Fine, Anthony L.

Mayo Clinic

Epilepsia Open | September 18, 2025 | Volume: 10 | Issue: 6 | Pages: 1835-1846

10.1002/epi4.70144 | PMID 40965114 Get It

Abstract Objective The objective of this study is to characterize contemporary surgical management practices and factors influencing surgical decision‐making in the management of Lennox–Gastaut Syndrome (LGS) across pediatric epilepsy centers in the United States. Methods A 45‐item cross‐sectional survey was developed and distributed to Pediatric Epilepsy Research Consortium centers. Domains included institutional demographics, surgical evaluation timing and goals, presurgical workup, procedural utilization and outcomes, and barriers to surgery. Descriptive statistics and thematic analysis were performed. Results Thirty‐two pediatric epilepsy centers participated (38% response), the majority comprising pediatric epileptologists at Level 4 National Association of Epilepsy Centers. Most centers (66%) considered surgery after failure of 3–4 antiseizure medications. Presurgical workup typically included brain magnetic resonance imaging (MRI), long‐term electroencephalography (EEG) monitoring, and neuropsychological assessment, while use of functional imaging, magnetoencephalography, and intracranial EEG varied considerably. All centers offered vagus nerve stimulation and corpus callosotomy; 80%–90% offered resection, hemispherectomy, responsive neurostimulation (RNS); 60%–65% offered deep brain stimulation (DBS) and laser ablation. Among centers offering RNS, half targeted thalamic structures exclusively, and the remainder targeted cortical or combined cortical‐thalamic structures; the centromedian nucleus was the preferred thalamic target for RNS and DBS. Surgical decision‐making was influenced by patient characteristics, procedural considerations, and systemic factors. Seizure frequency, family preference, and multidisciplinary input were highly rated across all interventions. Etiology was critical for resection and hemispherectomy, while financial constraints, insurance barriers, and the need for future neuroimaging impacted neuromodulation selection. Scenario‐specific trends included less frequent consideration of DBS and RNS in children under five years, less use of hemispherectomy in older children, preference for corpus callosotomy in children with predominantly drop seizures, and procedural selection based on MRI findings. Significance Substantial variability exists in the surgical management of LGS. These findings highlight critical opportunities to harmonize practices, reduce disparities, and guide comparative effectiveness research to optimize outcomes. Plain Language Summary Lennox–Gastaut Syndrome (LGS) is a severe form of epilepsy that may require surgery when medications are not effective. This study found that surgical care for LGS varies widely across pediatric epilepsy centers in the United States, including when surgery is recommended, how patients are evaluated, and which procedures are available. Newer approaches such as brain stimulation are being used more often, although access remains inconsistent. These findings highlight the need for clearer treatment pathways to ensure that children with LGS have equitable access to the best possible care.
Cortisol Testing to Diagnose Adrenal Insufficiency Following Adrenalectomy for Mild Autonomous Cortisol Secretion
Hamidi, Oksana , Salama, Bahaa , Findling, James W. , Zhang, Catherine D , Dream, Sophie , Balderrama-Brondani, Vania , Dackiw, Alan P.B., Mirfakhraee, Sasan , Mehta, Ankeeta , McKenzie, Travis J. , Foster, Trenton R. , Findling, James W , Balderrama-Brondani, Vania , Mirfakhraee, Sasan , Foster, Trenton, Bancos, Irina , Hamidi, Oksana , Wang, Tracy S. , Carroll, Ty B , Sada, Alaa , Dogra, Prerna , Oltmann, Sarah Catherine , Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 12, 2025 | Volume: 111 | Issue: 3 | Pages: 665-678

10.1210/clinem/dgaf515 | PMID 40966719 Get It

Abstract Context Patients with mild autonomous cortisol secretion (MACS) can develop adrenal insufficiency after unilateral adrenalectomy. Objective This work aimed to determine the prevalence, duration, and predictors of adrenal insufficiency, and compare postoperative basal cortisol and cosyntropin stimulation test (CST). Methods In this multicenter retrospective study of patients with MACS, adrenal insufficiency was diagnosed when postoperative basal cortisol was less than 10 µg/dL and/or CST < 18 µg/dL. The results were concordant when both tests met cutoffs. Biochemical (BSS) and clinical severity scores (CSS) were calculated. Results Among 281 patients with MACS (80% women), postoperative adrenal insufficiency was diagnosed in 153 (54.5%) patients. Adrenal insufficiency inversely correlated with age (odds ratio [OR] 0.67 per 10 years; 95% CI, 0.53-0.84). Low basal cortisol and CST were associated with younger age (OR 0.64 per 10 years for both) and higher BSS (OR 1.17 and 1.22, respectively). Basal cortisol and CST were discordant in 22% of patients, and the discordance rate was more common in patients with bilateral nodules (32% vs 19%; P < .001). The median time to adrenal insufficiency recovery was 3.9 months (IQR, 3-5.9 months), with longer duration associated with higher BSS and CSS: 3 months for mild, 4 to 5 months for moderate, and 12 to 14 months for severe BSS and CSS. Conclusion Approximately half of patients with MACS developed postoperative adrenal insufficiency, with 50% recovering by 3.9 months after surgery. BSS correlated with basal cortisol, CST, and duration of adrenal insufficiency. As discordant results were noted in 22%, performing both basal cortisol and CST postoperatively should be considered.
Characteristics of Transfusion and Association With Oncologic Outcomes in Hepatoblastoma Resection
Polites, Stephanie F. , Aldrink, Jennifer H. , Lautz, Timothy B. , Malek, Marcus M. , Fleming, Andrew M. , Roach, Jonathan P. , Radhakrishnan, Sridharan, Piché, Nelson , Osman, Yasmin, Lovvorn, Harold N. , Favela, Juan , Marquart, John , Craig, Brian T. , Seemann, Natashia M. , Petroze, Robin T. , Rich, Barrie S. , Glick, Richard D. , Selesner, Leigh , Fialkowski, Elizabeth , Boehmer, Chloé , Malek, Marcus M , Reiter, Audra , Murphy, Andrew J , Kastenberg, Zachary J , Tracy, Elisabeth T , Seemann, Natashia M , Rich, Barrie S , Fialkowski, Elizabeth A , Lautz, Timothy , Aldrink, Jennifer H , Vierkant, Robert A. , Chen, Stephanie , Kim, Eugene S. , Rinehardt, Hannah , Murphy, Andrew J. , Radhakrishnan, Sridharan, Kastenberg, Zachary J. , Tracy, Elisabeth T. , Le, Hau D. , Lal, Dave R. , Yoo, Ashley , Brown, Erin G. , Dasgupta, Roshni , Langham, Max Raymond

Mayo Clinic

Pediatric Blood & Cancer | September 3, 2025 | Volume: 72 | Issue: 12 | Pages: No page available

10.1002/pbc.32029 | PMID 40899404 Get It

ABSTRACT Introduction Children with hepatoblastoma (HB) and other solid tumors frequently undergo intraoperative blood transfusion (IBT) with unknown impact on oncologic outcomes and scant data to guide transfusion in this population. This study tested the hypothesis that IBT is associated with poorer survival in children with HB. Methods A multicenter retrospective observational study of patients aged <18 years with HB who underwent primary tumor resection, including liver transplantation, from 2010 to 2019 was performed at 19 institutions. The association of IBT with risk of recurrence and death were determined using propensity score reweighted (PSR) Cox proportional hazards regression analyses. Results There were 338 patients identified who met inclusion criteria and had sufficient data for inclusion. Of those, 257 (76%) received IBT, including 253 (98%) who received packed red blood cells (pRBC), 84 (33%) who received plasma, and 28 (11%) who received platelets. IBT was associated with higher pretreatment extent of disease ( p < 0.001), presence of annotation factors (+VPEFR: 50%, n = 129 vs. 37%, n = 30, p = 0.035), and complex resections (extended, meso‐, or total hepatectomy: 54%, n = 139 vs. 27%, n = 22, p < 0.001); these differences were mitigated after applying propensity score weighting. Patients who received IBT had greater postoperative hemoglobin (g/dL) (median 10 (I8–11) vs. 9 (8–10), p = 0.013) and required more postoperative plasma and platelet transfusions ( p < 0.05). Median follow‐up was 4.4 (2.0–8.3) years. Compared with non‐IBT patients, those with IBT had higher incidence of death (PSR HR 2.35, 95% CI 1.10–5.02). Recurrence did not significantly differ across groups (PSR HR = 0.82, 95% CI 0.45–1.48). Conclusion IBT was associated with greater hazard of death. Postoperative hemoglobin levels suggested that unnecessary transfusions occurred and a pRBC‐focused approach to IBT led to coagulopathy. Development of optimal transfusion strategies for HB are needed to minimize unnecessary transfusions.
Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer
Ligibel, Jennifer A. , McCall, Linda, Goodwin, Pamela J. , Bernstein, Vanessa , Delahanty, Linda M. , Hahn, Olwen, Hopkins, Judith O. , Irwin, Melinda L. , Minasian, Lori M. , Nebeling, Linda , Neuhouser, Marian L., Paskett, Electra D., Spears, Patricia A. , Stearns, Vered, Thomson, Cynthia A. , Weiss, Anna , White, Julia , Wadden, Thomas A., Hudis, Clifford A. , Ballman, Karla V. , Alfano, Catherine M. , Crane, Tracy E. , Frank, Elizabeth S. , Hershman, Dawn L. , Mayer, Erica L. , Paskett, Electra D. , Winer, Eric P. , Partridge, Ann H. , Carey, Lisa A.

Mayo Clinic

JAMA Oncology | August 21, 2025 | Volume: 11 | Issue: 10 | Pages: 1194

10.1001/jamaoncol.2025.2738 | PMID 40839373 Get It

Importance Obesity is associated with a higher risk of recurrence, mortality, comorbidities, treatment-related adverse effects, and poor quality of life in patients with breast cancer. Scalable interventions are needed to promote weight loss in this population. Objective To evaluate the impact of a remotely delivered weight loss intervention (WLI) on weight change at 1 year in patients with breast cancer and obesity and to explore factors associated with weight change. Design, Setting, and Participants The Breast Cancer Weight Loss trial is a phase 3, randomized clinical trial evaluating the impact of a telephone-based WLI on invasive disease–free survival and other outcomes in women with obesity and early breast cancer at 637 sites across the US and Canada. Participants were enrolled to the study between August 2016 and February 2021. Participants included women with stage II to III, ERBB2 -negative breast cancer and a body mass index (BMI) of 27 or higher. Interventions Participants were randomized to a 2-year, telephone-based WLI plus health education or health education alone control group. Main Outcome and Measures The primary end point for this prespecified secondary analysis was weight change at 1 year. Weight was measured at baseline and 1 year, and changes in weight were compared between groups. Weight change was evaluated with a linear mixed-effects model including treatment group, weight over time, a time-by-group interaction, menopausal status, race and ethnicity, and hormone receptor status. Results A total of 3180 women with breast cancer and BMI of 27 and higher were included in the study; 1591 were randomized to the WLI and 1589 to the control group. At baseline, the mean (SD) age of participants was 53.4 (10.6), and the mean (SD) BMI was 34.4 (5.6). The racial and ethnic breakdown included 406 (12.8%) Black, 231 (7.3%) Hispanic or Latino, 2906 (91.4%) non-Hispanic, and 2555 (80.3%) White participants. WLI participants lost a mean of 4.3 kg (95% CI 3.9-4.6 kg), or 4.7% (95% CI, 4.3%-5.0%) of baseline body weight at 1 year vs control participants, who gained 0.9 kg (95% CI, 0.5-1.3 kg), or 1.0% (95% CI 0.1%-1.4%) of baseline body weight ( P &amp;lt; .001). Participants randomized to WLI experienced significant weight loss (vs control group participants) across demographic and tumor factors. WLI effect differed significantly by menopausal status, with postmenopausal participants having greater weight loss than premenopausal participants, and by race and ethnicity, with Black and Hispanic participants having less weight loss compared to other races and ethnicities. Conclusions and Relevance In this secondary analysis of a randomized clinical trial, a telephone-based WLI induced significant weight loss in patients with breast cancer with overweight and obesity across demographic and treatment factors. Further follow-up of the Breast Cancer Weight Loss trial will evaluate whether the WLI improves disease outcomes. Trial Registration ClinicalTrials.gov Identifier: NCT02750826
Measuring the Risk of Gluten Exposure: Development of the Gluten Exposure Risk Assessment in Pediatric Patients
Hale, Amy E. , Germone, Monique , Fahey, Lisa M. , Stahl, Marisa G. , Leonard, Maureen M. , Singh, Arunjot , Hajjat, Temara , Mallon, Daniel , Kerzner, Benny, Raber, Catherine , Badalyan, Vahe , Mehta, Pooja , Liu, Edwin , Shull, Mary , Absah, Imad , Ediger, Tracy , Jericho, Hilary , Khavari, Nasim, Jossen, Jackie , Wolf, Randi L. , Wong, Madison , Regis, Stephanie , Weisbrod, Vanessa , Silvester, Jocelyn A. , RAISE-CD, Stahl, Marisa , Verma, Ritu , Jericho, Hilary , Wolf, Randi L , Regis, Stephanie , Weisbrod, Vanessa , Silvester, Jocelyn A , Mallon, Daniel , Lee, Dale Young , RAISE-CD

Mayo Clinic

American Journal of Gastroenterology | July 30, 2025 | Volume: 121 | Issue: 5 | Pages: 1251-1258

10.14309/ajg.0000000000003675 | PMID 40736693 Get It

INTRODUCTION: Treatment of celiac disease (CeD) requires a strict gluten-free diet (GFD). Adherence is difficult to assess and influenced by many factors. Identification of potential gluten exposures is essential, but no validated screening measures exist in pediatrics. The aim of this study was to develop and validate a measure screening for gluten exposure risk in pediatric patients with CeD. METHODS: The Gluten Exposure Risk Assessment (GERA) was developed in 3 phases. First, items were generated and refined by a modified Delphi process. Next, psychometrics, factor structure, and validity were examined in a sample of caregivers of pediatric patients younger than 18 years with CeD at 12 pediatric celiac centers. Finally, the final measure was tested on an independent sample population using confirmatory factor analysis and test-retest data. RESULTS: A total of 134 items were generated representing up to 6 domains, with 36 items selected for initial testing. Based on psychometrics and confirmatory factor analysis data from 484 caregivers, the final measure included a total of a single screening question and 9 validated items representing 2 domains (Home, Outside). Repeat testing on a separate sample (N = 369) confirmed factor structure and validity of the final measure (Comparative Fit Index = 0.96, Tucker–Lewis index = 0.95, root mean square error of approximation = 0.06). DISCUSSION: The GERA is a valid screening measure, completed by caregivers, for assessment of gluten exposure in children and adolescents with CeD following a GFD. GERA is a useful tool for evaluating the potential of risk of gluten exposure and potential need for intervention.
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, Patrick Y. , Lee, Eudocia Q. , Khasraw, Mustafa , Rahman, Rifaquat , Platten, Michael , Lim, Michael , Verhaak, Roel G.W. , Albert, Nathalie L. , Schiff, David , Ostrom, Quinn T. , Aldape, Kenneth , Batchelor, Tracy T. , Chiocca, E. Antonio, DeGroot, John, French, Pim J. , Hegi, Monika E. , Lassman, Andrew B. , Mellinghoff, Ingo K. , Minniti, Giuseppe, Taphoorn, Martin , Weiss, von Deimling, Tobias, Zadeh, Gelareh , Reardon, David A. , Chang, Susan M. , Short, Susan , Weller, Michael , Touat, Mehdi , Khasraw, Mustafa , Platten, Michael , Winkler, Frank , Verhaak, Roel Gw , Albert, Nathalie L , Tonn, Joerg-Christian , Barnholtz-Sloan, Jill S , Cloughesy, Timothy F , French, Pim J , Galanis, Evanthia , Galldiks, Norbert , Mellinghoff, Ingo K , Roth, Patrick , Sanson, Marc , Wick, Wolfgang , Reardon, David A , Short, Susan C , Ostrom, Quinn T , Wen, Patrick Yung , Horbinski, Craig , Huang, Raymond Y. , Ahluwalia, Manmeet S. , Barnholtz‐Sloan, Jill S. , Bindra, Ranjit S. , Cloughesy, Timothy F. , Galanis, Evanthia , Gilbert, Mark R. , Rhun, Émilie Le , Mehta, Minesh P. , Roth, Patrick , Sanson, Marc , Weiss, von Deimling, Tobias, Wick, Wolfgang , Bent, Martin J. van den , Preusser, Matthias

Mayo Clinic

Neuro-Oncology | July 22, 2025 | Volume: 27 | Issue: 11 | Pages: 2751-2788

10.1093/neuonc/noaf177 | PMID 40827022 Get It

Abstract Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021, the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict glioblastomas to isocitrate dehydrogenase-wildtype (IDHwt) tumors, improving understanding of the prognosis and optimal therapy for these tumors. This revision also enables more homogeneous populations of patients to be enrolled in clinical trials, facilitating the evaluation of novel therapies. In this updated consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of patients with glioblastoma is discussed. In addition, novel therapies such as immunotherapies, viral therapies, targeted molecular therapies, theranostics, and antibody–drug conjugates will be reviewed, as well as the current challenges and future directions for research.
SAR Consensus Recommendations for Defining Small Bowel Crohn Disease Strictures at CT and MR Enterography
Dillman, Jonathan R. , Fidler, Jeff L. , Anupindi, Sudha A. , Fulmer, Clifton G. , Gordon, Ilyssa O. , Bruining, David H. , Deepak, Parakkal , Abualruz, Abdul Rahman , Al-Hawary, Mahmoud M. , Altinmakas, Emre , Guglielmo, Flavius F. , Jaffe, Tracy A. , Rieder, Florian , Baker, Mark E. , Dane, Bari , Dillman, Jonathan R , Fidler, Jeff L. , Anupindi, Sudha A , Fulmer, Clifton , Gordon, Ilyssa O , Bruining, David Henry , Deepak, Parakkal , Abualruz, Abdul-Rahman , Al-Hawary, Mahmoud , Guglielmo, Flavius F , Jaffe, Tracy , Bettenworth, Dominik , Rieder, Florian , Fletcher, Joel G , Baker, Mark E , Rimola, Jordi , Fletcher, Joel G.

Mayo Clinic

Radiology | July 15, 2025 | Volume: 316 | Issue: 1 | Pages: No page available

10.1148/radiol.243123 | PMID 40662968 Get It

This consensus by the Society of Abdominal Radiology Inflammatory Bowel Disease Disease Focused Panel provides an updated imaging-based definition of small bowel Crohn disease stricture for CT and MR enterography.
An international inter‐rater agreement study in the challenging diagnosis of squamous dysplasia of the oesophagus
Patil, Ameya , Jiezhen, Tracy Loh, Kosiorek, Heidi , Brown, Ian , Carneiro, Fátima , Gill, Anthony J. , Kumarasinghe, Priyanthi , Kushima, Ryoji , Sheahan, Kieran , Shepherd, Neil A. , Slavík, Tomáš , Lauwers, Gregory Y. , Langner, Cord , Pai, Rish K. , Brown, Ian S , Kumarasinghe, Priyanthi M , Srivastava, Amitabh , Lauwers, Gregory Y , Langner, Cord , Pai, R K , Kosiorek, Heidi E , Srivastava, Amitabh

Mayo Clinic

Histopathology | July 8, 2025 | Volume: 87 | Issue: 4 | Pages: 573-583

10.1111/his.15509 | PMID 40625062 Get It

AimsThere is a lack of published literature on the diagnostic reproducibility of oesophageal squamous dysplasia using a two‐tiered grading system.Methods and resultsWe identified 75 oesophageal biopsies, which were reviewed by 10 international pathologists twice (1500 total observations) with a > 4‐week washout period. Between rounds, a consensus meeting refining diagnostic criteria was held and an atlas was created to provide illustrations. Overall agreement was fair with kappa of 0.35 and 0.32 in round 1 and 2, respectively. Agreement was moderate to fair for negative for dysplasia (ND) (round 1 = 0.41 and round 2 = 0.34) and poor for indefinite for dysplasia (IND) and low‐grade dysplasia (LGD) (kappa <0.2). Agreement for high‐grade dysplasia (HGD) was good in both rounds (round 1 = 0.64; round 2 = 0.61). In round 1, majority diagnosis (MDx, ≥6 of 10 raters agreeing) was seen in 51 (68%) cases with the majority classified as ND (N = 27) or HGD (N = 18). MDx was rarely achieved for LGD (N = 6). In round 2, MDx was seen in 49 (65%) cases (20 ND, 1 IND, 11 LGD and 17 HGD). Of the 40 cases with MDx for both rounds, 39 were concordant (15 HGD, 6 LGD and 18 ND).ConclusionsOverall agreement among pathologists in diagnosing squamous lesions is fair; however, HGD had good agreement. This study fills an important gap in our knowledge of the inter‐rater variability in the diagnosis of oesophageal squamous dysplasia.
COVID-19 and Cognitive Change in a Community-Based Cohort
Pike, James Russell , Sun, Yifei , Wu, Christina , Suchy‐Dicey, Astrid M. , Elkind, Mitchell S.V., Kucharska‐Newton, Anna , Levine, Deb, Lutsey, Pamela L. , Mosley, Thomas H. , Palta, Priya, Coresh, Josef, Oelsner, Elizabeth C. , Lutsey, Pamela L , Pike, James R , Oelsner, Elizabeth C , Kucharska-Newton, Anna M , Demmer, Ryan T. , Cornelius, Talea M. , Kraal, A. Zarina , Balte, Pallavi , Wu, Chaoqi, Allen, Norrina B. , Cushman, Mary , Howard, Virginia J. , Manly, Jennifer J. , Power, Melinda C. , Seshadri, Sudha , Tracy, Russell P. , Walker, Keenan A.

Mayo Clinic

JAMA Network Open | June 30, 2025 | Volume: 8 | Issue: 6 | Pages: e2518648

10.1001/jamanetworkopen.2025.18648 | PMID 40587126 Get It

Importance SARS-CoV-2 infection has been linked to neurotoxic effects and cognitive deficits. Objective To determine whether decreases in cognitive function were accelerated after SARS-CoV-2 infection compared with individuals not infected. Design, Setting, and Participants Multicenter, prospective cohort study from 2016 to 2022 among 3525 participants alive on March 1, 2020, and enrolled in The Atherosclerosis Risk in Communities (ARIC) study and the Collaborative Cohort of Cohorts for COVID-19 Research study who completed a prepandemic cognitive assessment and a pandemic-era assessment of SARS-CoV-2 infection. Final analyses performed in November 2024. Exposure SARS-CoV-2 infection determined via self-report of a positive SARS-CoV-2 test or health care professional diagnosis of COVID-19, a positive SARS-CoV-2 antinucleocapsid antibody response, or presence of an administrative code for COVID-19 on medical records. Main outcomes and measures A neuropsychological battery assessed multiple cognitive domains, and a cocalibrated confirmatory factor analysis generated factor scores for global cognitive function. The primary outcome was the rate of excess change in cognitive function. Results The 3525 eligible participants had a mean (SD) age of 80.8 (4.7) years, 2085 (59.1%) were female, 752 (21.4%) were Black, and 2773 (78.6%) were White. SARS-CoV-2 infection was detected among 307 participants (8.7%), 103 of whom (33.6%) were hospitalized. Among uninfected participants, the mean annualized change in cognitive function was −0.09 (95% CI, −0.13 to −0.04). Compared with this rate, change was faster (β = −0.06; 95% CI, −0.09 to −0.02) among participants hospitalized for infection, but not different from participants who were infected but not hospitalized (β = 0.00; 95% CI, −0.02 to 0.03). The association among participants hospitalized for infection was evident in the cognitive domains of memory and executive function, but not language. Conclusions and relevance This cohort study of older participants found accelerated decreases in cognition among individuals hospitalized for SARS-CoV-2 infection, but not nonhospitalized infection, in comparison with individuals not yet infected.